Welcome to our dedicated page for CompuMed news (Ticker: CMPD), a resource for investors and traders seeking the latest updates and insights on CompuMed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CompuMed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CompuMed's position in the market.
CompuMed, a leader in remote diagnostic services for organ donation and transplantation, partners with FireStarter, a marketing firm, to enhance organ donation efforts in the U.S. The collaboration aims to combine telediagnostic solutions with effective marketing strategies to increase organ donations and save more lives. CompuMed's advanced technologies and expertise have earned the trust of 60% of OPOs, leading to the partnership with FireStarter to further support organ recovery teams and transplant centers.
Summary not available.
Summary not available.
Summary not available.
LOS ANGELES, CA / ACCESSWIRE / March 22, 2023 / CEO Lee Keddie of CompuMed has joined The Alliance National Innovation Leadership Council, which aims to foster collaboration in organ donation and transplantation. His leadership has significantly contributed to CompuMed's reputation as a top provider of clinical organ analysis, enhancing the efficiency of organ utilization and improving the lives of those involved in the process. Keddie's dedication to innovation in this field has been acknowledged through this prestigious appointment, which allows him to further influence organ transplantation practices and outcomes. CompuMed offers rapid diagnostic services through top specialists in telemedicine.
CompuMed, Inc. (OTC PINK:CMPD) reported fiscal 2022 fourth quarter revenue of $1.59 million, a 9.8% increase from last year, and annual revenue of $6.37 million, up 0.8%. However, net income decreased to $231,000 in Q4, down from $480,000 in the prior year. The company’s cash and accounts receivable position was $2.85 million, down 6.9% year-over-year. Despite customer attrition, CompuMed aims to accelerate adoption of new products. Adjusted for one-time costs, recurring net income stands at $726,000. Book value increased to $3.85 million, reflecting a 14.6% rise.
CompuMed, Inc. (OTC PINK:CMPD) reports its fiscal 2022 third-quarter results. Revenue rose 2.1% from the previous quarter but fell 7.4% year-over-year, having faced tough comparisons from record earnings last year. Operating income reached $136,000, a 155% increase from the previous quarter, yet down 46% from a year earlier. Cash and accounts receivable remained stable at $2,628,000. The company indicated ongoing investments in marketing may drive future sales growth.
CompuMed, Inc. (OTC PINK:CMPD) has implemented a 1-for-25 reverse stock split effective May 23, 2022, as approved by shareholders on March 15, 2022. This action consolidates 42,291,070 shares down to 1,691,643 shares, ensuring no change in par value. A temporary 'D' will be added to the ticker symbol, changing back to CMPD after 20 business days. Fractional shares will be settled in cash. The company will maintain share records through Computershare Trust Company in a book-entry format. Shareholders can request physical stock certificates if desired.
CompuMed, Inc. (OTC PINK:CMPD) reported Q2 fiscal 2022 results with revenue of $1.6 million, slightly down from $1.63 million in Q2 2021, but up 3.9% from the previous quarter. The company's operating income was $53,000, reflecting a significant decrease of 56% sequentially and 67% year-over-year, largely due to non-recurring legal costs. Cash and accounts receivable totaled $2.6 million, down 7% from Q1 2022. CompuMed has not utilized most of its $1 million share buyback authorization, indicating a cautious financial strategy.
CompuMed, Inc. (OTC PINK:CMPD) announced a 25:1 reverse stock split approved by stockholders in March 2022. The company is finalizing documents with FINRA and its transfer agent, ComputerShare, to implement this split, expected by mid-May 2022. CompuMed specializes in diagnostic telemedicine, offering services like telecardiology and teleradiology to provide affordable, real-time access to U.S. Board-Certified specialists. The company has been operational for over 26 years, servicing 1,000+ clinical settings worldwide.
FAQ
What is the current stock price of CompuMed (CMPD)?
What is the market cap of CompuMed (CMPD)?
